DEFECTIVE MISMATCH REPAIR AND BENEFIT FROM BEVACIZUMAB FOR COLON CANCER

摘要

Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF munition is also of significance.